Page 44 - Read Online
P. 44
Genvigir et al. J Transl Genet Genom 2020;4:320-55 I http://dx.doi.org/10.20517/jtgg.2020.37 Page 329
Ref. Ref. [14] [34] [40] [13] [51] [52] [29] [35] [27]
Clinical outcomes Clinical outcomes No association of UGT1A9 c.-275T>A variant with gastrointestinal adverse No association of UGT1A9 c.-275T>A and c.98T>C variants with AR or adverse UGT1A9 c.98TC genotype was associated with decreased graft function UGT1A9 c.98TC genotype was associated with lower eGFR, but not with AR and No association of UGT1A9 c.-2152C>T and c.-275T>A variants with AR or adverse No association of UGT1A9 c.-215
- events - events DGF events -
Pharmacokinetics Pharmacokinetics No association of UGT1A9 c.-2152C>T, c.-440C>T, c.-275T>A and c.98T>C variants with MPA or MPAG pharmacokinetics - No association of UGT1A9 c.-2152C>T, c.- 275T>A and c.98T>C pharmacokinetics - - - - UGT1A9 c.-440CT (or c.-331TC) and -1818CC genotypes were associated with higher and lower MPAG AUC 0-12 , respectively -
Immunosuppressive Immunosuppressive regimen regimen MMF Cyclosporine Tacrolimus Sirolimus Corticosteroids At a point between 3-6 months MMF Cyclosporine Tacrolimus Sirolimus Up to 115 month follow- up MMF Cyclosporine Tacrolimus Corticosteroids Sixty-day variants with MPA follow-up MMF Cyclosporine Tacrolimus mTOR inhibitor Corticosteroids One-year follow-up MMF Calcineurin inhibitors Corticosteroids One-year follow-up MMF
Population Population 89 pediatric patients 103 adult patients 140 adult patients 284 pediatric and young adult patients (USA)
185 patients (France) 256 adult patients (France) (France) 218 adult patients (France) (Poland) (Poland) 189 adult patients (France) 127 adult patients (China)
Study design Study design Prospective (included multicenter Apomygre study) Retrospective Prospective, multicenter Retrospective (Transgene study) Retrospective (Case- control) Retrospective Prospective, multicenter (Dominos study) Prospective Retrospective (Case- control) multicenter
Allele frequency Allele frequency c.-2152T: 6% c.-440T: 24% c.-275A:6% c.98C: 3% c.-275A: 6% c.-2152T: 4% c.-275A: 6% c.98C: 2% c.-275A: 7% c.98C: 1% c.-2152T: 5% c.-275A: 4% c.98C: 3% c.98C: 4% c.-2152T: 3% c.-275A: 5% -1818T: 13% c.-440T: 2% c.-331C: 2% -118delT: 58% I399C: 31% -
Variant Variant
Gene Gene